Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Asian Pac J Cancer Prev ; 22(3): 681-690, 2021 Mar 01.
Article in English | MEDLINE | ID: covidwho-1155072

ABSTRACT

OBJECTIVE: The COVID-19 pandemic has dramatically affected healthcare services around Asia. The Asian National Cancer Centres Alliance and the Asia-Pacific Organisation for Cancer Prevention collaborated to assess the mid- and long- term impact of COVID-19 to cancer care in Asia. METHODS: The two entities organised a combined symposium and post-meeting interactions among representatives of major cancer centres from seventeen Asian countries to outlining major challenges and countermeasures. RESULTS: Participating stakeholders distilled five big questions. 1) "Will there be an explosion of late-stage cancers after the pandemic?" To address and recover from perceived delayed prevention, screening, treatment and care challenges, collaboration of key stakeholders in the region and alignment in cancer care management, policy intervention and cancer registry initiatives would be of essential value. 2) "Operations and Finance" The pandemic has resulted in significant material and financial casualties. Flagged acute challenges (shortages of supplies, imposition of lockdown) as well as longer-standing reduction of financial revenue, manpower, international collaboration, and training should also be addressed. 3) "Will telemedicine and technological innovations revolutionize cancer care?" Deploying and implementing telemedicine such as teleconsultation and virtual tumour boards were considered invaluable. These innovations could become a new regular practice, leading to expansion of tele-collaboration through collaboration of institutions in the region. 4) "Will virtual conferences continue after the pandemic?" Virtual conferences during the pandemic have opened new doors for knowledge sharing, especially for representatives of low- and middle-income countries in the region, while saving time and costs of travel. 5) "How do we prepare for the next pandemic or international emergency?" Roadmaps for action to improve access to appropriate patient care and research were identified and scrutinised. CONCLUSION: Through addressing these five big questions, focused collaboration among members and with international organisations such as City Cancer Challenge will allow enhanced preparedness for future international emergencies.
.


Subject(s)
COVID-19 , Cancer Care Facilities/organization & administration , Neoplasms/epidemiology , Telemedicine , Asia/epidemiology , Cancer Care Facilities/economics , Communicable Disease Control , Congresses as Topic , Delayed Diagnosis , Delivery of Health Care , Humans , Neoplasms/diagnosis , Neoplasms/pathology , Neoplasms/therapy , SARS-CoV-2 , Videoconferencing
2.
JAMA Oncol ; 7(4): 597-602, 2021 04 01.
Article in English | MEDLINE | ID: covidwho-1012157

ABSTRACT

Importance: The coronavirus disease 2019 (COVID-19) pandemic has burdened health care resources and disrupted care of patients with cancer. Virtual care (VC) represents a potential solution. However, few quantitative data support its rapid implementation and positive associations with service capacity and quality. Objective: To examine the outcomes of a cancer center-wide virtual care program in response to the COVID-19 pandemic. Design, Setting, and Participants: This cohort study applied a hospitalwide agile service design to map gaps and develop a customized digital solution to enable at-scale VC across a publicly funded comprehensive cancer center. Data were collected from a high-volume cancer center in Ontario, Canada, from March 23 to May 22, 2020. Main Outcomes and Measures: Outcome measures were care delivery volumes, quality of care, patient and practitioner experiences, and cost savings to patients. Results: The VC solution was developed and launched 12 days after the declaration of the COVID-19 pandemic. A total of 22 085 VC visits (mean, 514 visits per day) were conducted, comprising 68.4% (range, 18.8%-100%) of daily visits compared with 0.8% before launch (P < .001). Ambulatory clinic volumes recovered a month after deployment (3714-4091 patients per week), whereas chemotherapy and radiotherapy caseloads (1943-2461 patients per week) remained stable throughout. No changes in institutional or provincial quality-of-care indexes were observed. A total of 3791 surveys (3507 patients and 284 practitioners) were completed; 2207 patients (82%) and 92 practitioners (72%) indicated overall satisfaction with VC. The direct cost of this initiative was CAD$ 202 537, and displacement-related cost savings to patients totaled CAD$ 3 155 946. Conclusions and Relevance: These findings suggest that implementation of VC at scale at a high-volume cancer center may be feasible. An agile service design approach was able to preserve outpatient caseloads and maintain care quality, while rendering high patient and practitioner satisfaction. These findings may help guide the transformation of telemedicine in the post COVID-19 era.


Subject(s)
Ambulatory Care/organization & administration , COVID-19 , Cancer Care Facilities/organization & administration , Delivery of Health Care, Integrated/organization & administration , Medical Oncology/organization & administration , Telemedicine/organization & administration , Tertiary Care Centers/organization & administration , Ambulatory Care/economics , Appointments and Schedules , Attitude of Health Personnel , Cancer Care Facilities/economics , Cost Savings , Cost-Benefit Analysis , Delivery of Health Care, Integrated/economics , Feasibility Studies , Health Care Costs , Health Expenditures , Humans , Medical Oncology/economics , Ontario , Patient Satisfaction , Program Development , Program Evaluation , Quality Indicators, Health Care/organization & administration , Telemedicine/economics , Tertiary Care Centers/economics , Time Factors , Workload
3.
Oncol Res Treat ; 43(6): 307-313, 2020.
Article in English | MEDLINE | ID: covidwho-211348

ABSTRACT

With the outbreak of the COVID-19 pandemia, routine clinical work was immediately, deeply, and sustainably impacted in Germany and worldwide. The infrastructure of almost all hospitals is currently redirected to provide a maximum of intensive care resources, including the necessary staff. In parallel, routine as well as emergency clinical care for all patients in need has to be secured. This challenge becomes particularly evident in cancer care. In order to maintain adequate oncological care at all levels of provision and to conduct especially curative and intensive treatments with a maximum of safety, continuous adaption of the oncology care system has to be ensured. Intensive communication with colleagues and patients is needed as is consequent expert networking and continuous reflection of the own developed strategies. In parallel, it is of high importance to actively avoid cessation of innovation in order not to endanger the continuous improvement in prognosis of cancer patients. This includes sustained conduction of clinical trials as well as ongoing translational research. Here, we describe measures taken at the University Cancer Center Hamburg (UCCH) - a recognized comprehensive oncology center of excellence - during the COVID-19 crisis. We aim to provide support and potential perspectives to generate a discussion basis on how to maintain high-end cancer care during such a crisis and how to conduct patients safely into the future.


Subject(s)
Betacoronavirus , Cancer Care Facilities/organization & administration , Coronavirus Infections/prevention & control , Hospitals, University/organization & administration , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Ambulatory Care , COVID-19 , Cancer Care Facilities/economics , Coronavirus Infections/economics , Coronavirus Infections/virology , Germany , Hospitals, University/economics , Humans , Infection Control/methods , Inpatients , Pandemics/economics , Patient Safety , Pneumonia, Viral/economics , Pneumonia, Viral/virology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL